MS4A1 membrane spanning 4-domains A1
ENSG00000156738 · protein coding · Open Targets profile
B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes (PubMed:12920111, PubMed:3925015, PubMed:7684739). Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR (PubMed:12920111, PubMed:18474602, PubMed:7684739). {ECO:0000269|PubMed:12920111, ECO:0000269|PubMed:18474602, ECO:0000269|PubMed:3925015, ECO:0000269|PubMed:7684739}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand
- Antibody
- Approved Drug, UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM, Human Protein Atlas loc
- PROTAC
- Database Ubiquitination, Half-life Data
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.6031000018119812 (upper bound 0.9160000085830688). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 400 registry trials, updated in the last three years, of the most advanced drugs against MS4A1 (obinutuzumab, mosunetuzumab, tositumomab, epcoritamab, odronextamab, glofitamab, ublituximab, ocrelizumab, tositumomab 131i, MT-3724, ocaratuzumab, yttrium y 90 ibritumomab tiuxetan), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Dai ChiharaUT MD Anderson Cancer Center · 6 of 6 trials Phase 2+Ph2NCT07917832 · Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphomabrief
- Nitin JainM.D. Anderson Cancer Center · 4 of 4 trials Phase 2+Ph2NCT02629809 · Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemiabrief
- Joseph M TuscanoCity of Hope Comprehensive Cancer Center LAO · 3 of 4 trials Phase 2+Ph1NCT06015880 · Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphomabrief
- Marco LadettoDepartment of Translational Medicine of the Università degli Studi del Piemonte Orientale, Novara, Italy. AO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy. · 3 of 3 trials Phase 2+
- Mengyang DiFred Hutch/University of Washington Cancer Consortium · 3 of 3 trials Phase 2+
- Shuhua YiInstitute of Hematology & Blood Diseases Hospital, China · 3 of 3 trials Phase 2+
- Steven LE GOUILLNantes University Hospital · 3 of 3 trials Phase 2+
- Swetha KambhampatiCity of Hope Medical Center · 3 of 3 trials Phase 2+
- Alexey V DanilovCity of Hope Medical Center · 2 of 3 trials Phase 2+
- Christopher J MelaniECOG-ACRIN Cancer Research Group · 2 of 3 trials Phase 2+
- Stephen E SpurgeonOHSU Knight Cancer Institute · 2 of 3 trials Phase 2+Ph1/Ph2NCT06249191 · Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphomabrief
- Barbara EichhorstUniversitätsklinikum Köln · 2 of 2 trials Phase 2+
- Fernando FervenzaMayo Clinic · 2 of 2 trials Phase 2+
- Jae ParkMemorial Sloan Kettering Cancer Center · 2 of 2 trials Phase 2+
- Jason WestinM.D. Anderson Cancer Center · 2 of 2 trials Phase 2+
Registry trials of obinutuzumab, mosunetuzumab, tositumomab, epcoritamab, odronextamab, glofitamab, ublituximab, ocrelizumab, tositumomab 131i, MT-3724, ocaratuzumab, yttrium y 90 ibritumomab tiuxetan updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 265 of 387 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 13 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
123 trials of drugs against MS4A1 were stopped early; 6 give no reason
Terminated, withdrawn and suspended interventional trials of obinutuzumab, mosunetuzumab, tositumomab, epcoritamab, odronextamab, glofitamab, ublituximab, ocrelizumab, tositumomab 131i, MT-3724, ocaratuzumab, yttrium y 90 ibritumomab tiuxetan, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 123.
- terminated · 2026-10-23 · Genmab · Epcoritamab“The study was terminated because sufficient data had been collected to meet the objectives of the development program. No new or unexpected safety findings were identified, and the decision to terminate was not related to participant safety.”
- terminated · 2026-10-15 · Maria Sklodowska-Curie National Research Institute of Oncology · Obinutuzumab“Following the recommendation of the Data Monitoring Committee (DMC), based on the results of the interim analysis, the Sponsor has decided to terminate the study prematurely”
- terminated · 2026-06-16 · Servier Bio-Innovation LLC · matched by the registry's drug synonyms“Sponsor decision to terminate during Phase 1”
- terminated · 2026-05-06 · Pfizer · Glofitamab, Obinutuzumab“Business/Administrative decision to pursue other programs/assets within the oncology portfolio. Not due to any detected safety signals or requests from regulatory authorities.”
- terminated · 2026-05-06 · Mayo Clinic · Obinutuzumab“Funding was withdrawn by sponsor.”
- withdrawn · 2026-04-07 · Memorial Sloan Kettering Cancer Center · Epcoritamab“Lack of accrual”
- suspended · 2026-01-21 · City of Hope Medical Center · Epcoritamab“Pending Interim Analysis”
- withdrawn · 2025-11-28 · The University of Queensland · Obinutuzumab“The study was deemed unfeasible due to unforeseen financial limitations”
- withdrawn · 2025-09-17 · M.D. Anderson Cancer Center · Glofitamab“PI Request”
- terminated · 2025-07-22 · University of Washington · Obinutuzumab“Study terminated to end of funding.”
- terminated · 2025-07-09 · Mayo Clinic · matched by the registry's drug synonyms“drug supply issues”
- terminated · 2025-06-17 · Gilead Sciences · Obinutuzumab“The goal of the study was to improve tolerability while maintaining or increasing efficacy. The results of this study showed no efficacy advantage although the combinations were well tolerated.”
- terminated · 2025-05-26 · Mayo Clinic · Obinutuzumab“funding - sponsor filing Chapter 11 bankruptcy”
- terminated · 2025-05-13 · State University of New York at Buffalo · matched by the registry's drug synonyms“Lack of recruitment”
- suspended · 2025-04-30 · Indapta Therapeutics, INC. · Ocrelizumab“Business Reasons”
- terminated · 2025-04-29 · Celgene · Obinutuzumab“Business objectives have changed.”
- terminated · 2025-04-10 · MingSight Pharmaceuticals, Inc · obinutuzumab“The study is terminated due to major protocol revisions. A new study in CLL patients is planned.”
- terminated · 2025-01-15 · Hoffmann-La Roche · Ocrelizumab“The study was terminated earlier as the study sponsor collected sufficient data to perform all analyses as per pre-specified endpoints in the study protocol.”
- terminated · 2024-12-13 · TG Therapeutics, Inc. · Obinutuzumab, Ublituximab“Strategic/Business decision”
- terminated · 2024-11-21 · Fondazione Italiana Linfomi - ETS · Obinutuzumab“Study was halted prematurely due to safety, since tocity stopping rules have been met”
- terminated · 2024-10-24 · University of Wisconsin, Madison · Obinutuzumab“slow accrual”
- terminated · 2024-10-24 · Genmab · Epcoritamab“Due to strategic evaluation of GEN3009 within context of Genmab's portfolio, decision not based on any safety or regulatory concerns.”
- terminated · 2024-10-09 · Yale University · Ocrelizumab“Slow enrollment”
- terminated · 2024-10-04 · Hoffmann-La Roche · Mosunetuzumab SC“Study was terminated due to Sponsor decision.”
- terminated · 2024-08-23 · Hoffmann-La Roche · Glofitamab, Obinutuzumab“The study was terminated due to sponsor portfolio re-alignment.”
Paediatric incentives and obligations for MS4A1's drugs
For obinutuzumab, mosunetuzumab, tositumomab, epcoritamab, odronextamab, glofitamab, ublituximab, ocrelizumab, tositumomab 131i, MT-3724, ocaratuzumab, yttrium y 90 ibritumomab tiuxetan: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: yes · MS4A1 is on the list. Membership alone neither requires nor waives a pediatric study.Rule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMA/PE/0000237224 (ocrelizumab, Treatment of multiple sclerosis): PM: decision on the application for modification of an agreed PIP, 14 Apr 2025; EMA/PE/0000181993 (mosunetuzumab, Treatment of mature B-cell neoplasms): PM: decision on the application for modification of an agreed PIP, 8 Nov 2024; EMEA-001207-PIP06-22 (obinutuzumab, Prevention of cytokine release syndrome induced by anti CD20/CD3 antibodies): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), date not given; EMEA-002907-PIP01-20-M03 (Epcoritamab, Treatment of mature B-cell malignancies): PM: decision on the application for modification of an agreed PIP, 27 Jun 2024; +8 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/15/1504 withdrawn 19 Jun 2015: Treatment of follicular lymphoma; EU/3/21/2497 withdrawn 15 Oct 2021: Treatment of diffuse large B-cell lymphoma; EU/3/22/2656 withdrawn 18 Jul 2022: Treatment of diffuse large B-cell lymphoma; EU/3/22/2649 withdrawn 18 Jul 2022: Treatment of follicular lymphoma; +10 moreRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Columvi: authorised since 7 Jul 2023; Ocrevus: authorised since 8 Jan 2018; Lunsumio: authorised since 3 Jun 2022, orphan medicine, conditional; Ordspono: authorised since 22 Aug 2024, orphan medicine, conditional; +3 moreRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of obinutuzumab, mosunetuzumab, tositumomab, epcoritamab, odronextamab, glofitamab, ublituximab, ocrelizumab, tositumomab 131i, mt-3724, ocaratuzumab, yttrium y 90 ibritumomab tiuxetanRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 26 interventional studies of obinutuzumab, mosunetuzumab, tositumomab, epcoritamab, odronextamab, glofitamab, ublituximab, ocrelizumab, tositumomab 131i, mt-3724, ocaratuzumab, yttrium y 90 ibritumomab tiuxetan include patients under 18; 16 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 18 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.